Microbot Medical (MBOT) vs PolyPid (PYPD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PolyPid (PYPD) has outperformed Microbot Medical (MBOT) over the past year, gaining 42.9% versus a loss of 65.3%. Over five years, MBOT leads with a -84.4% price change compared with -97.8% for PYPD. PolyPid is the larger company by market cap ($99.5 million vs $71.9 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MBOT | PYPD |
|---|---|---|
| Share price | $1.07 | $4.90 |
| Market cap | $71.87M | $99.53M |
| 1-day change | -4.46% | -1.01% |
| YTD return | -44.00% | +12.90% |
| 1-year return | -65.33% | +42.86% |
| 5-year return | -84.38% | -97.83% |
| EPS (TTM) | $-0.25 | $-1.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.17 | $5.73 |
| 52-week low | $1.05 | $3.06 |
| Distance from 52-week high | -66.25% | -14.49% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +491.59% | +139.80% |
| Average volume | 649.10K | 176.73K |
| Shares outstanding | 67.16M | 20.31M |
| Employees | 43 | 69 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PYPD has outperformed MBOT by 108.2 percentage points over the past year.
About Microbot Medical
MBOT stock →Microbot Medical Inc. is a medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space.
Healthcare · Medical Devices · 43 employees
About PolyPid
PYPD stock →PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.
Healthcare · Biotechnology · 69 employees
MBOT vs PYPD FAQ
Which is bigger, Microbot Medical or PolyPid?
PolyPid (PYPD) is larger, with a market capitalization of $99.53M compared with $71.87M for Microbot Medical (MBOT).
Which stock has performed better over the past year, MBOT or PYPD?
PYPD returned +42.86% over the past 12 months, compared with -65.33% for MBOT (price return, excluding dividends). Past performance does not predict future results.
Are Microbot Medical and PolyPid in the same industry?
Both are in the Healthcare sector, but in different industries: Medical Devices for Microbot Medical and Biotechnology for PolyPid.